Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Curis
Thumbnail
May 04, 2022

The Irak-4 approach has a wobble

Thumbnail
December 23, 2021

Key data reveals for the small players

Praxis, Proqr and Nordic Nanovector are awaiting important data.

Article image
Vantage logo
November 15, 2021

SITC 2021 – Incyte unveils its oral checkpoint blocker

There are some remissions, but peripheral neuropathy casts a long shadow.

Article image
Vantage logo
July 21, 2021

Not yet time for Tim-3

Article image
Vantage logo
June 14, 2021

EHA 2021 movers – more fallers than risers

Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.

Article image
Vantage logo
May 13, 2021

EHA 2021 – Curis’s renaissance continues

Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.

Article image
Vantage logo
May 10, 2021

Chemocentryx’s future in doubt as avacopan foundation crumbles

Article image
Vantage logo
February 10, 2021

Early clinical data provided the wild ride for investors in 2020

Article image
Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.

Article image
Vantage logo
January 26, 2021

Novartis goes up against Glaxo in Tim-3

Article image
Vantage logo
January 13, 2021

Serometrix's oral work attracts Esperion

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.